What Nektar Therapeutics's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 16 |
| Total trades | 7 | 26 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 10,000 | 12,772 |
| Disposed | 604 | 33,058 |
| Net activity | +9,396 | −20,287 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Greer R Scott | Director | Sep 23 | Grant / award · A | +2,000 | — | — | 22,239 |
| Brainard Diana | Director | Sep 23 | Grant / award · A | +2,000 | — | — | 3,904 |
| Chess Robert | Director | Sep 23 | Grant / award · A | +2,000 | — | — | 19,019 |
| Whitfield Roy A | Director | Sep 23 | Grant / award · A | +2,000 | — | — | 16,417 |
| Ajer Jeffrey Robert | Director | Sep 23 | Grant / award · A | +2,000 | — | — | 4,277 |
| Zalevsky Jonathan | Chief R&D Officer | Aug 18 | Sale for tax withholding · S | −186 | $71.98 | −$13.4K | 9,570 |
| Robin Howard W | President & CEO | Aug 18 | Sale for tax withholding · S | −418 | $71.98 | −$30.1K | 54,627 |
| Zalevsky Jonathan | Chief R&D Officer | Jun 30 | Disclosed 10b5-1 sale · S | −5,681 | $70.00 | −$398K | 9,756 |
| Robin Howard W | President & CEO | Jun 17 | Disclosed 10b5-1 sale · S | −4,500 | $61.65 | −$277K | 55,045 |
| Robin Howard W | President & CEO | Jun 17 | Disclosed 10b5-1 sale · S | −5,500 | $60.81 | −$334K | 59,545 |
| Robin Howard W | President & CEO | Jun 16 | Disclosed 10b5-1 sale · S | −4,697 | $60.71 | −$285K | 65,045 |
| Robin Howard W | President & CEO | Jun 16 | Disclosed 10b5-1 sale · S | −5,303 | $59.97 | −$318K | 69,742 |
| Zalevsky Jonathan | Chief R&D Officer | Jun 15 | Disclosed 10b5-1 sale · S | −5,538 | $60.71 | −$336K | 15,437 |
| Robin Howard W | President & CEO | May 19 | Sale for tax withholding · S | −444 | $65.51 | −$29.1K | 75,045 |
| Zalevsky Jonathan | Chief R&D Officer | May 19 | Sale for tax withholding · S | −199 | $65.51 | −$13K | 20,975 |
| Zalevsky Jonathan | Chief R&D Officer | Feb 18 | Sale for tax withholding · S | −180 | $73.00 | −$13.1K | 21,174 |
| Robin Howard W | President & CEO | Feb 18 | Sale for tax withholding · S | −423 | $73.00 | −$30.9K | 75,489 |
| Zalevsky Jonathan | Chief R&D Officer | Jan 20 | Disclosed 10b5-1 sale · S | −3,867 | $35.67 | −$138K | 21,354 |
| Zalevsky Jonathan | Chief R&D Officer | Dec 22 | Grant / award · A | +6,250 | — | — | 25,221 |
| Robin Howard W | President & CEO | Dec 22 | Grant / award · A | +21,667 | — | — | 75,912 |
Loading...
